Amgen settles investor suit over $10.7B IRS tax disputeDimension closes third fund at $800MLupin spins out two oncology programmesBrenus lands €11M series A extension UK first to approve lower-carbon asthma inhalers Amgen settles investor suit over $10.7B IRS tax disputeAmgen has agreed to pay $74 million to settle a US lawsuit accusing the drugmaker of keeping shareholders in the dark about a possible $10.7-billion tax battle with the Internal Revenue Service (IRS). The proposed class-action settlement, filed in Manhattan federal court this week, still requires approval from a judge.The suit alleged Amgen had failed to adequately warn investors about the potential impact of an IRS challenge targeting the company's transfer pricing practices between 2010 and 2015. The IRS claims Amgen underreported taxes by improperly allocating profits to a Puerto Rico-based manufacturing unit, thereby reducing its US tax obligations, and is seeking $8.7 billion in back taxes plus interest, along with $2 billion in penalties.Shareholders led by the Asbestos Workers Philadelphia Pension Fund argued that Amgen's delayed disclosures caused its stock price to fall 6.5% on Aug. 4, 2021, and 4.3% on April 28, 2022, when additional details of the tax dispute emerged. The settlement covers investors between July 29, 2020, and April 27, 2022.In late 2024, a federal judge allowed the proposed class action to proceed after rejecting Amgen's attempt to dismiss the case.-Anna BratulicDimension closes third fund at $800MVenture capital firm Dimension said Tuesday it has raised $800 million for its third funding, bringing its total assets under management to $1.65 billion. Since launching in 2023, the VC has invested in a slew of companies developing machine learning technologies, including those geared towards medicine. It has founded newcos, backed private financings, and participated in IPOs. Most recently, Dimension participated in a $400-million series C for Chai, a firm developing AI for drug discovery. According to the VC, its investment model "prioritises rigorous understanding of the technologies, sciences, and markets we seek to invent or disrupt," which span "the frontiers of science and compute."-Elizabeth EatonLupin spins out two oncology programmesLupin said Tuesday it spun out two oncology programmes — LNP7457 and LNP8701 — into Kaveri Therapeutics, a US-based company that will take the candidates through global clinical development.As per the transaction's terms, Lupin will hold a substantial equity stake in Kaveri, offer seed funding and grant the latter exclusive rights to the programmes. Kaveri, led by chief executive Kristi Jones, will operate independently and continue seeking additional capital to finance R&D efforts. LNP7457, a PRMT5 inhibitor, and LNP8701, an SOS1 inhibitor, reported favourable Phase I data at the American Society of Clinical Oncology (ASCO) meetings in 2025 and 2026, respectively.-Pavan KamatBrenus lands €11M series A extension Brenus Pharma raised an €11-million ($12.6 million) series A extension, bringing the French biotech's total funding since inception to €38 million ($43.5 million).The round drew support from existing backers, including Angelor, UI Investissement, Crédit Agricole, Noshaq, Orsa, BIO JAG and Bpifrance, alongside two new investors in Sambrinvest and Korea Omega Investment.The fresh financing will support the continued early-stage testing of STC-1010, Brenus' lead oncology vaccine programme for microsatellite-stable metastatic colorectal cancer, whilst also prepping the company's in vivo immunotherapy platform for advancing the next asset.-Pavan KamatUK first to approve lower-carbon asthma inhalersRegulators in the UK approved new versions of Chiesi's asthma treatment Clenil Modulite (beclometasone dipropionate), making it the first authorisation of a pressurised metered-dose inhaler (pMDI) that uses the next-generation propellant HFA-152a in an effort to reduce environmental impact.The product, which comes in 100-mcg and 200-mcg strengths, is approved for the maintenance treatment of asthma in adults and children. The Medicines and Healthcare products Regulatory Agency (MHRA) noted that the new versions — which have been shown to perform comparably to currently authorised products — will be available later in 2026. Julian Beach, MHRA executive director of healthcare quality and access, said the approval "demonstrates how innovation can support both patient care and environmental sustainability while maintaining the high standards of quality, safety and effectiveness patients expect." -Matt Dennis